NEW ORLEANS, June 18, 2008 (PRIME NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today presented promising preclinical results on pretargeted therapy of pancreatic cancer that can be further improved when given in small fractions repeatedly, and in combination with gemcitabine.
